Amicus Therapeutics Inc Q4 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : I saw at World recently that you shared some subgroup analyses from the PROPEL trial. So I wanted to ask if you could discuss your strategy with some of these particular data sets and how this might help you aid in conversations if commercialized outside of already having the advantage of having the clinical experience in both the ERT switch and naive patients.

Question: Yun Zhong - BTIG, LLC, Research Division - Analyst : So I have a follow-up question on ERT switch patients Pompe for AT-GAA. So one piece of the input that we have heard from physicians is that if patients are stable on existing ERT, they would like to keep those patients on their current therapy. So I don't know -- so do you think that those patients who are starting to show loss of response to existing Myozyme or Lumizyme could be in probably the easier patient population to target? And for those patients who are stable on existing ERT, what do you believe would be the strongest evidence to convince those physicians that maybe switch is a good idea?

Question: Gil Joseph Blum - Needham & Company, LLC, Research Division - Analyst : Considering the fact that you might have a little bit more flexibility, would Amicus consider in-licensing some new program that fits well with the core strategy around Fabry and Pompe?

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : I just want to ask 2 quick ones. First is, in your mid-cycle review with the FDA on AT-GAA, was there any indication that a advisory committee meeting will be convened? And secondly, given your workforce rationalization, any thoughts around the Batten disease gene therapy franchise? How should we think about the potential there?